Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech
A little more than a year after an ambitious Takeda came in with a $1 billion-plus package to collaborate with Mersana on its antibody/drug constructs, the Cambridge, MA-based biotech has pulled the trigger on a $75 million IPO.
The offering follows a collaboration with Merck KGaA as well, which was also attracted to the biotech’s boast that it can create ADCs to go after diseases that are currently beyond the reach of the current generation of armed antibodies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
